Nasdaq · CIK 0002088082
ETRA Electra Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 18 d ago. Close $9.04 on Oct 9, 2026, 0% from the 52-week low and -35% from the high.
Last 90 days
Net insider value
+$40M
more bought than sold
Buys
2
$40M by 2 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
ETRAOct 9, 2026 · close 9.04
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Electra Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | Orbimed Advisors LLC director, owner buy | $20M 1,333,333 shares | +28% | - | |
| 54Moderate | Carl L Gordon director, owner buy | $20M 1,333,333 shares | +28% | - |
Transactions
The last 28 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +2,002,310 | - | - | 2,002,310 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +2,002,310 | - | - | 2,002,310 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +1,087,934 | - | - | 3,090,244 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +1,087,934 | - | - | 3,090,244 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +1,703,314 | - | - | 4,793,558 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +1,703,314 | - | - | 4,793,558 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +333,333 | $15.00 | $5.0M | 5,126,891 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +333,333 | $15.00 | $5.0M | 5,126,891 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Common Stockindirect: See footnotes | +758,279 | - | - | 758,279 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +758,279 | - | - | 758,279 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,758,279 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,758,279 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnotes | -2,002,310 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnotes | -2,002,310 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnotes | -1,087,934 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnotes | -1,087,934 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -1,703,314 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -1,703,314 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Carl L Gordon director, owner | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -758,279 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Orbimed Advisors LLC director, owner | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -758,279 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | Graham Parry Chief Scientific Officer | CConversion Common Stock | +85,504 | - | - | 85,504 | 20 d ago |
| Sep 21, 2026 | Gary S. Koe Chief Technical Officer | CConversion Common Stock | +63,656 | - | - | 63,656 | 20 d ago |
| Sep 21, 2026 | Nancy Stagliano director | CConversion Common Stock | +255,635 | - | - | 255,635 | 20 d ago |
| Sep 21, 2026 | Quehuong (Kathy) Dong President & CEO | CConversion Common Stock | +455,484 | - | - | 455,484 | 20 d ago |
| Sep 21, 2026 | Graham Parry Chief Scientific Officer | CConversion Series A Convertible Preferred Stockderivative | -85,504 | - | - | 0 | 20 d ago |
| Sep 21, 2026 | Gary S. Koe Chief Technical Officer | CConversion Series A Convertible Preferred Stockderivative | -63,656 | - | - | 0 | 20 d ago |
| Sep 21, 2026 | Nancy Stagliano director | CConversion Series A Convertible Preferred Stockderivative | -255,635 | - | - | 0 | 20 d ago |
| Sep 21, 2026 | Quehuong (Kathy) Dong President & CEO | CConversion Series A Convertible Preferred Stockderivative | -455,484 | - | - | 0 | 20 d ago |
Insiders
Everyone who has filed a Form 4 here.
- Quehuong (Kathy) DongPresident & CEO
- Carl L Gordondirector, owner
- Gary S. KoeChief Technical Officer
- Orbimed Advisors LLCdirector, owner
- Graham ParryChief Scientific Officer
- Nancy Staglianodirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.